COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISK

被引：0
作者：
Garcia-Goni, M. [1 ]
Facila, L. [2 ]
Cinza, S. [3 ]
Pinto, X. [4 ]
Cortes, X. [5 ]
Prades, M. [6 ]
Aceituno, S. [6 ]
机构：
[1] Univ Complutense, Madrid, Spain
[2] Hosp Gen Univ Valencia, Valencia, Spain
[3] Porto Do Son Primary Care Hlth Ctr, La Coruna, Spain
[4] Hosp Bellvitge Princeps Espanya, Lhospitalet De Llobregat, Spain
[5] Almirall SA, Barcelona, Spain
[6] Outcomes 10, Castellon De La Plana, Spain
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.620
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV74
引用
收藏
页码：S104 / S105
页数：3
相关论文
共 50 条
[21]   Cost-effectiveness analysis of rosuvastatin in Greek patients with hyperlipidaemia [J].
Papageorgiou, M ;
Karokis, A ;
Plumb, JM ;
Ratcliffe, A ;
Southworth, H .
VALUE IN HEALTH, 2003, 6 (06) :654-654
[22]   A cost-effectiveness analysis of carotid artery stenting compared to endarterectomy in high risk populations [J].
Young, Kate C. ;
Holloway, Robert G. ;
Burgin, W. S. ;
Benesch, Curtis G. .
CIRCULATION, 2008, 117 (21) :E425-E425
[23]   The cost-effectiveness of atorvastatin, rosuvastatin and simvastatin in treating patients to LDL-cholesterol targets [J].
Niskanen, L. ;
Peura, P. K. ;
Hallinen, T. ;
Soini, E. ;
Martikainen, J. .
EUROPEAN HEART JOURNAL, 2007, 28 :860-860
[24]   Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events [J].
Capri, S ;
Perlini, S .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (06) :913-921
[25]   Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review [J].
Jankovic, Slobodan M. ;
Tesic, Danka ;
Andelkovic, Jelena ;
Kostic, Marina .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (05) :461-474
[26]   COST-EFFECTIVENESS OF ICOSAPENT ETHYL FOR PATIENTS AT HIGH CARDIOVASCULAR RISK WITH ELEVATED TRIGLYCERIDES IN GREECE [J].
Stratopoulos, A. ;
Kougioumtzoglou, I ;
Mortaki, K. ;
Rigopoulos, P. ;
Jakouloff, D. .
VALUE IN HEALTH, 2023, 26 (12) :S51-S51
[27]   Cost-effectiveness of pharmacist care for managing patients at high risk for cardiovascular disease in Canada [J].
Al Hamarneh, Y. N. ;
Johnston, K. ;
Marra, C. ;
Tsuyuki, R. .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) :297-298
[28]   A COST EFFECTIVENESS ANALYSIS OF ROSUVASTATIN AGAINST ATORVASTATIN IN CARDIOVASCULAR DISEASES AND STROKE: AN AMBISPECTIVE STUDY [J].
Deepthy, B. .
VALUE IN HEALTH, 2016, 19 (07) :A653-A653
[29]   Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis [J].
Yang, Han ;
Li, Nan ;
Zhou, Youlian ;
Xiao, Zhilan ;
Tian, Haoming ;
Hu, Ming ;
Li, Sheyu .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 :157-165
[30]   Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico [J].
Martinez, Juan Pablo Diaz ;
de Maraumont, Therese Aubry ;
Sanchez, Elly Natty ;
Cordero, Luis Miguel Camacho ;
Yeh, Eric .
PLOS ONE, 2025, 20 (02)
12345